Induction of ovulation in women undergoing assisted reproductive techniques: Recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP)

Human Reproduction

Volumn 15, Issue 5, 2000, Pages 1021-1027

  Lenton, E ^a   Soltan, A ^a   Hewitt, J ^b   Thomson, A ^b   Davies, W ^c   Ashraf, N ^c   Sharma, V ^d   Jenner, L ^d   Ledger, W ^e   McVeigh, E ^e  

^a Sheffield Fertility Centre   (United Kingdom)

^b LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^c BMI Three Shires Hospital   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Highly purified human uFSH; Human rFSH; ICSI; IVF; Multiple follicular development

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; FOLLITROPIN ALPHA FRAGMENT; GONADOTROPIN; PROGESTERONE; RECOMBINANT FOLLITROPIN; UROFOLLITROPIN; UROFOLLITROPIN HP;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOSIS; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; MALE INFERTILITY; MULTICENTER STUDY; OOCYTE; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION;

FALLOPIA;

EID: 17344390250     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.5.1021     Document Type: Article

References (38)

1. Abu-Heija, A.T., Yates, R.W.S., Barrett, T. et al. (1995) A comparison of two starting doses of human menopausal gonadotrophin for follicle stimulation in unselected patients for in-vitro fertilization. Hum. Reprod., 10, 801-803.
2. Albano, C., Smitz, J., Camus, M. et al. (1996) Pregnancy and birth in an in-vitro fertilization cycle after controlled ovarian stimulation in a woman with a history of allergic reactions to human menopausal gonadotrophin. Hum. Reprod., 11, 1632-1634.
3. Bergh, C., Howles, C.M., Borg, K. et al. (1997) Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F®) versus highly purified urinary FSH (Metrodin HP®): results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum. Reprod., 12, 2133-2139.
4. Brinsden, P., Akagbosu, F., Gibbons, L. et al. (2000) A comparison of the efficacy and tolerability of two recombinant human FSH preparations in IVF-ET. Fertil. Steril., 73, 114-116.
5. Camier, B., Avril, C., Cohen, J. et al. (1998) A multicentre, prospective, randomised study to compare a low dose protocol versus conventional administration of recombinant human follicle stimulating hormone (Gonal-F®) in normo-responder women undergoing IVF/ICS1 (abstract). 14th Annual Meeting of the European Society of Human Reproduction and Embryology, Gothenburg, Sweden, 21-24 June. Hum. Reprod., 13 (Abstract Bk. 1), P-058.
6. Chappel, S., Kelton, C. and Nugent, N. (1992) Expression of human gonadotropins by recombinant DNA methods. In Genazzani, A.R. and Petraaglia, F. (eds), Proceedings of the 3rd World Congress on Gynaecological Endocrinology. Parthenon Publishing Group, Carnforth, UK, pp. 179-184.
7. Daya, S., and Gunby, J. (1999) Recombinant versus urinary follicle-stimulating hormone for ovarian stimulation in assisted reproduction. Hum. Reprod., 14, 2207-2215.
8. Daya, S., Gunby, J., Hughes, E.G. et al. (1995) Follicle-stimulating hormone versus human menopausal gonadotrophin for in vitro fertilization cycles: a meta-analysis. Fertil. Steril., 64, 77-86.
9. Delvigne, A., Dubois, M., Battheu, B. et al. (1993) The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum. Reprod., 8, 1361-1366.
10. Devroey, P., Mannaerts, B., Smitz, J. et al. (1994) Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens. Hum. Reprod., 9, 1064-1069.
11. Devroey, P., Tournaye, H., Van Steirteghem, A. et al. (1998) The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon®) in in-vitro fertilization. Hum. Reprod., 13, 565-566.
12. Fisch, B., Avrech, O.M., Pinkas, H. et al. (1995) Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): a comparative study. J. Assist. Reprod. Genetics, 12, 26-31.
13. Fried, G., Harlin, J. and Wramsby, H. (1998) Recombinant FSH - clinical experience with two different preparations. Fertil. Steril., 70 (Suppl. 1), S112.
14. Frydman, R., Avril, C., Camier, B. et al. (2000) A double-blind, randomised study comparing the efficacy of r-hFSH/Gonal-F® and u-hFSH HP/Metrodin HP® in inducing ovulation in women undergoing assisted reproductive techniques (ART). Hum. Reprod., 15, 520-525.
15. Hamberger, L. and Wikland, M. (1993) Controversies in assisted reproduction. Natural versus stimulated cycles for IVF. J. Assoc. Reprod. Genet., 10, 405-406.
16. Hamilton, M., Shaaban, M., Bhattacharya, S. et al. (1998) IVF versus ICSI in non-male factor infertility: a multicentre prospective, randomised controlled trial (abstract). Fertil. Steril., 70 (Suppl. 1), 0-252, S94.
17. Hedon, B., Out, H.J., Hugues, J.N. et al. (1995) Efficacy and safety of recombinant follicle stimulating hormone (Puregon®) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial. Hum. Reprod., 10, 3102-3106.
18. Homburg, R., Armar, N.A., Eshel, A. et al. (1988) Influence of serum luteinizing hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovarian syndrome. Br. Med. J., 297, 1024-1026.
19. Howles, C.M., Loumaye, E., Giroud, D. and Luyet, G. (1994) Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation (Metrodin High Purity) in pituitary desensitized women undergoing IVF-ET: a multicentre European Phase III study. Hum. Reprod., 9, 424-430.
20. Hughes, E.G., Fedorkow, D.M., Daya, S. et al. (1992) The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil. Steril., 58, 888-896.
21. Jansen, C.A.M., van Os, H.C., Out, H.J. and Coelingh-Bennink, H.J.T. (1998) A prospective, randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon®) and human menopausal gonadotrophins (Humegon®) in non-down-regulated in-vitro fertilization cycles. Hum. Reprod., 13, 2995-2999.
22. Khalaf, Y., Taylor, A. Pettigrew, R. et al. (2000) The relative clinical efficacy of recombinant follicle stimulating hormone to the highly purified urinary preparation. Assist. Reprod. Rev. (in press).
23. Loumaye, E. (1990) The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum. Reprod., 5, 357-376.
24. Loumaye, E., Campbell, R. and Salat-Baroux, J. (1995) Human follicle-stimulating hormone produced by recombinant DNA technology: a review for clinicians. Hum. Reprod. Update, 1, 188-199.
25. Mannaerts, B.M.L.L, Rombout, F., Out, H.J. and Coelingh-Bennink, H. (1996) Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Hum. Reprod. Update, 2, 153-161.
26. Olijve, W., De Boer, W., Mulders, J.W.M. et al. (1996) Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol. Hum. Reprod., 2, 371-382.
27. Out, H.J., Mannaerts, B.M.J.L., Driessen, S.G.A.J. and Coelingh-Bennink, H.J.T. (1995) A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon® versus Metrodin®) in in-vitro fertilization. Hum. Reprod., 10, 2534-2540.
28. Out, H.J., Reimitz, P.E. and Coelingh-Bennink, H.J.T. (1997) A prospective, randomized study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant follicle-stimulating hormone (Puregon®) Fertil. Steril., 67, 278-283.
29. Punnonen, R., Ashorn, R., Vilja, P. et al. (1988) Spontaneous luteinizing hormone surge and cleavage of in vitro fertilized embryos. Fertil. Steril., 49, 479-482.
30. Recombinant Human FSH Product Development Group (1998) Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Hum. Reprod. Update, 4, 862-881.
31. Recombinant Human FSH Study Group (1995) Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil. Steril., 63, 77-86.
32. Redfearn, A., Hughes, E.G., O'Connor, M. et al. (1995) Delayed-type hypersensitivity to human gonadotropin: case report. Fertil. Steril., 64, 855-856.
33. Smitz, J., Devroey, P., Braeckmans, P. et al. (1987) Management of failed cycles in an IVF-GIFT programme with the combination of a GnRH analogue and hMG. Hum. Reprod., 2, 309-314.
34. Stanger, J.D. and Yovich, J.L. (1985) Reduced in vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br. J. Obstet. Gynaecol., 92, 385-392.
35. Strowitzki, T., Kentenich, H., Kiesel, L. et al. (1995) Ovarian stimulation in women undergoing in vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F®) in non-down-regulated cycles. Hum. Reprod., 10, 3097-3101.
36. Templeton, A. and Morris, J.K. (1998) Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. New Engl. J. Med., 339, 573-577.
37. Thornton, S.J. (1996) Starting doses in IVF and effects on outcome (abstract). Hum. Reprod., 11, 104.
38. Wikland, M., Borg, J., Hamberger, L. and Sulander, P. (1994) Simplification of IVF, minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Hum. Reprod., 9, 1430-1436.